← Back to Clinical Trials
Recruiting NCT07836998

NCT07836998 A Study to Assess the Efficacy of an Experimental Mouthwash Used With a Marketed Whitening Toothpaste on Stain Build-up

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07836998
Status Recruiting
Phase —
Sponsor HALEON
Condition Tooth Discoloration
Study Type INTERVENTIONAL
Enrollment 360 participants
Start Date 2026-09-25
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Whitening ToothpasteExperimental MouthwashRegular Fluoride Toothpaste

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 360 participants in total. It began in 2026-09-25 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this clinical study is to evaluate the efficacy of an experimental mouthwash used with a marketed whitening toothpaste or a marketed regular fluoride toothpaste, compared to a marketed regular fluoride toothpaste alone, in preventing extrinsic dental stain build-up.

Eligibility Criteria

Inclusion Criteria: * Participant provision of a signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed. * Participant is willing and able to comply with scheduled visits, treatment/application/dosing plan, study restrictions, lifestyle considerations and other study procedures. * A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the ability to understand and follow study procedures and requirements. * At Visit 1 (Screening/Baseline): 1. Participant with good oral health. 2. Participant with at least 16 natural teeth including the 12 anterior teeth. 3. Participant with all facial surfaces, and mandibular lingual surfaces, of the 12 anterior teeth gradable for the MLSI. 4. Participant with presence of extrinsic dental stain (judged to be formed due to ingestion of food or drinks, or use of tobacco products) on the facial surfaces of the anterior teeth, as determined from a gross visual stain assessment. 5. Participant with before Prophylaxis (Baseline)- Total MLSI \[A multiplied by(x) I\] score ((four sites per tooth) of more than equal to (\>=) 15 on the facial surfaces of the six maxillary and six mandibular anterior teeth. Note: Total MLSI score (A x I), scored pre-prophylaxis, will be used for stratification, and is derived from the sum of the A x I scores of the facial surfaces of the six maxillary and six mandibular anterior teeth. Exclusion Criteria: * Participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or, a Haleon employee directly involved in the conduct of the study or a member of their immediate family. * A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation. * A participant with, in the opinion of the investigator (or medically qualified designee), an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study. * A participant who is pregnant (self-reported) or intending to become pregnant over the duration of the study. * A participant who is breastfeeding. * A participant with known or suspected intolerance or hypersensitivity to any study materials (or closely related compounds) or any of their stated ingredients. * Participant who is unwilling or, in the opinion of the investigator or medically qualified designee, unable to comply with the requirements and/or lifestyle restrictions of the study. * Participant with a recent history (within the last year) of alcohol or other substance abuse. * Participant with Oral soft tissue (OST) examination findings at Screening which, in the opinion of the investigator, could interfere with the conduct of the study (for example, stomatitis, open sores, lesions, cavitied caries lesions, redness or swelling. * Participant using daily oral care products and/or taking daily doses of medications/treatments which, in the opinion of the investigator or medically qualified designee, could interfere with study outcomes, specifically: 1. Currently daily use of mouthwashes containing ingredients known to cause tooth stain (for example, chlorhexidine or cetylpyridinium chloride). 2. Past or current use of minocycline. 3. Use of tetracycline or doxycycline within 30 days of Screening and/or during the study 4. Daily dose of medications known to cause tooth stain (for example, drugs or supplements containing metal ions known to increase enamel staining). * Participant who has used any professionally dispensed tooth whitening products 6 months prior to baseline or any over-the-counter tooth whitening products (including e.g., peroxide or blue dye containing toothpaste) 3 months prior to baseline. * Specific exclusions for assessment teeth: 1. Non-vital tooth. 2. Tooth with evidence of current or recent carious lesions. 3. Tooth used as an abutment for fixed or partial dentures. 4. Tooth adjacent to fixed retainers and fixed or removable orthodontic appliances. 5. Tooth with surface irregularities, cracked enamel, discoloration due to trauma or orthodontic treatment, tetracycline stain, restorations or hyper/hypoplastic areas, which, in the opinion of the clinical examiner, grading of extrinsic dental stain and tooth shade. 6. Tooth with a crown or veneer. 7. Tooth with exposed dentine which, in the opinion of the investigator, could impact grading of extrinsic dental stain. * General oral exclusions: 1. Generalized severe gingivitis or advanced periodontal disease; treatment of periodontal disease (including surgery) within 12 months of screening; scaling or root planning within 3 months of screening. 2. Any oral condition requiring immediate care. 3. Having received a dental prophylaxis within 8 weeks of screening. * A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.

Contact & Investigator

Central Contact

Haleon Response Center

✉ ww.clinical-trial-register@haleon.com

📞 +441932 95 95 00

Frequently Asked Questions

Who can join the NCT07836998 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Tooth Discoloration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07836998 currently recruiting?

Yes, NCT07836998 is actively recruiting participants. Contact the research team at ww.clinical-trial-register@haleon.com for enrollment information.

Where is the NCT07836998 trial being conducted?

This trial is being conducted at Melbourne, United States.

Who is sponsoring the NCT07836998 clinical trial?

NCT07836998 is sponsored by HALEON. The trial plans to enroll 360 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology